COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI HC QHC Q BHBH CICI BLBL NZNZ COCO BUBU More..
Home   
Share  
Tweet
  OutcomesOutcomes
3/15
Late Tolouian et al., J. Investig. Med., doi:10.1136/jim-2020-001747 (Peer Reviewed) death, ↓76.0%, p=0.43 Effect of bromhexine in hospitalized patients with COVID-19
Small RCT with 100 patients, 48 with bromhexine added to SOC, showing slower viral- conversion but lower mortality and greater clinical improvement with bromhexine (not statistically significant with few deaths and very high recovery). Th..
3/8
PrEP Mikhaylov et al., medRxiv, doi:10.1101/2021.03.03.21252855 (Preprint) hosp., ↓80.0%, p=0.49 Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study
Small prophylaxis RCT with 25 treatment and 25 control health care worker, showing lower PCR+, symptomatic cases, and hospitalization with treatment, although not statistically significant with the small sample size.
12/31
Review Al-Kuraishy et al., Current Medical and Drug Research (Review) (Peer Reviewed) review The potential role of Bromhexine in the management of COVID-19: Decipher and a real game-changer
Review article noting that bromhexine is a TMPRSS2 inhibitor with greater effect in lung tissue and attenuates the entry and proliferation of SARS‐CoV‐2.
12/3
Late Mareev et al., Кардиология, doi:10.18087/cardio.2020.11.n1440 (Peer Reviewed) no disch., ↓38.8%, p=0.02 Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)
Prospective 103 PCR+ patients in Russia, 33 treated with bromexhine+spironolactone. The odds ratio of having a positive PCR or hospitalization for ≥10 days was 0.07 [0.008–0.61] with treatment. Dosing was bromhexine 8mg 4 times daily, sp..
9/3
Early Li et al., Clinical and Translational Science, doi:10.1111/cts.12881 (Peer Reviewed) no disch., ↓75.0%, p=0.11 Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot Study
Tiny RCT with 12 bromhexine and 6 control patients showing non-statistically significant improvements in chest CT, need for oxygen therapy, and discharge rate within 20 days. Authors recommend a larger scale trial.
7/19
Early Ansarin et al., Bioimpacts, doi:10.34172/bi.2020.27 (Peer Reviewed) death, ↓90.9%, p=0.05 Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial
RCT with 39 bromhexine and 39 control patients showing lower mortality, intubation, and ICU admission with treatment. The treatment group received bromhexine hydrochloride 8 mg three times a day for two weeks. All patients received SOC in..
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit